Logotype for Pulse Biosciences Inc

Pulse Biosciences (PLSE) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Pulse Biosciences Inc

Q3 2026 earnings summary

6 Nov, 2026

Executive summary

  • NANOPULSE-AF completed enrollment three months ahead of plan, with 169 evaluable patients across 15 sites; pre-commercial preparation and launch readiness advanced.

  • Strategic focus remains nsPFA cardiac devices for AF, supported by a portfolio of more than 285 owned patents.

Financial highlights

  • Q3 revenue was $395,000 versus $86,000 YoY, primarily from limited-release Vybrance sales; commercial case volume increased sequentially.

  • Q3 GAAP costs and expenses were $24.7M versus $20.5M YoY; non-GAAP costs and expenses were $19.1M versus $14.6M.

  • GAAP net loss was $23.1M versus $19.4M YoY; non-GAAP net loss was $17.5M versus $13.5M.

  • Operating cash use was $15.3M versus $13.0M YoY and $18.7M in Q2; cash, cash equivalents and marketable securities totaled $189.2M at September 30, 2026.

  • Cost of product revenue was $191,000; disposable gross margins are expected to exceed 70% at scale.

Outlook and guidance

  • Final NANOPULSE-AF data, based on blended six- and 12-month follow-up, are expected in Q3 2027; CE Mark approval is anticipated in Q4 2027.

  • Launch preparation targets a launch beginning in early 2028, including manufacturing scale-up, market access, supply-chain and marketing plans.

  • Persistent-AF IDE submission is planned for Q4 2026; NANOCLAMP-AF enrollment is on track to finish by the end of H1 2027.

  • Quarterly non-GAAP costs and expenses are expected to rise 15%–25% above the Q2 and Q3 average, primarily for EP catheter activities.

  • PRECISE-BTN follow-up data are expected during 2027 to support a planned 510(k) submission for a benign thyroid nodule indication.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Pulse Biosciences